Lung Cancer Trials Ask AI to find trials
CompletedPhase 3NCT01285609
Official study title

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Study summary

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedIpilimumab and Placebo

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 18, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?290 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
  • Non small cell lung cancer (NSCLC) - squamous cell
  • Stage IV or recurrent NSCLC
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Reasons someone may not be able to joinExclusion criteria
  • Brain Metastases
  • Autoimmune diseases

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Sharp Memorial HospitalSan Diego, California
  • Va Connecticut Healthcare SystemWest Haven, Connecticut
  • Lynn Cancer Institute Center For Hematology-OncologyBoca Raton, Florida
  • Integrated Community Oncology NetworkJacksonville, Florida
  • University Of Illinois At Chicago Medical CenterChicago, Illinois
  • Quincy Medical GroupQuincy, Illinois
  • Presence Medical Group Hematology OncologySkokie, Illinois
  • Southern Illinois University School Of MedicineSpringfield, Illinois
  • St. Francis Hospital & Health CentersIndianapolis, Indiana
  • Floyd Memorial Cancer Center Of IndianaNew Albany, Indiana
  • Kentucky Cancer ClinicHazard, Kentucky
  • Norton Cancer InstituteLouisville, Kentucky

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 18, 2020. Always confirm current availability with the study team.

View original record ↗